(Q34584406)

3 August 2017

1 reference

title

Entecavir: a new nucleoside analog for the treatment of chronic hepatitis B infection. (English)

1 reference

3 August 2017

1 reference

1 reference

1 reference

Keri A Sims

1

1 reference

PubMed ID

17125436

3 August 2017

Abigail M Woodland

series ordinal

2

1 reference

PubMed ID

17125436

3 August 2017

language of work or name

English

0 references

publication date

1 December 2006

1 reference

3 August 2017

1 reference

3 August 2017

26

1 reference

3 August 2017

12

1 reference

3 August 2017

1745-1757

1 reference

Drug insight: Nucleoside and nucleotide analog inhibitors for hepatitis B.

3 August 2017

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1745

Drugs in development for hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1745

Natural history of hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1745

World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1745

A treatment algorithm for the management of chronic hepatitis B virus infection in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1745

Antiviral therapy for treatment-naïve hepatitis B virus patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1745

The treatment effect of alpha interferon in chronic hepatitis B is independent of pre-treatment variables. Results based on individual patient data from 10 clinical controlled trials. European Concerted Action on Viral Hepatitis (Eurohep).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1745

Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1745

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1745

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1745

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1745

Management of patients co-infected with hepatitis B virus and HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1745

Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1745

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1745

Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1745

Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1745

Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1745

Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1745

Histological outcome during long-term lamivudine therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1745

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1745

Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1745

Adefovir nephrotoxicity: possible role of mitochondrial DNA depletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1745

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1745

Clinical trial results of new therapies for HBV: implications for treatment guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1745

Entecavir: a potent new antiviral drug for hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1745

Current treatment of chronic hepatitis B: benefits and limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1745

Molecular virology of hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1745

Characterization of antiviral activity of entecavir in transgenic mice expressing hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1745

Potent efficacy of entecavir (BMS-200475) in a duck model of hepatitis B virus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1745

Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1745

In hepatocytes infected with duck hepatitis B virus, the template for viral RNA synthesis is amplified by an intracellular pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1745

Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1745

Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1745

A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1745

A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1745

Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1745

Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1745

Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1745

Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1745

Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1745

21 January 2018

Identifiers

DOI

10.1592/PHCO.26.12.1745

1 reference

3 August 2017

1 reference

PubMed ID

17125436